【摘要】 目的观察不同剂量密度伊立替康(CPT-11)联合LD-FP持续灌注治疗晚期大肠癌的近期疗效、生存期和毒副作用。方法采用两种方法对38例患者进行研究。每周剂量(A组)21例,3周剂量(B组)17例。A组:CPT-1160 mg/m2,iv,d1、8、15;B组:CPT-11 150 mg/m2iv,d1。两组分别联合5-Fu 300 mg/(m2.d),d1~14,微量泵持续静脉给药;DDP5 mg/d,d1~5,d8~14,iv;CF100 mg/(m2.d),d1~14,iv。28 d为1周期。结果A、B两组总有效率分别为20.0%和23.5%,中位肿瘤进展期(mTTP)均为5个月,中位生存期(MST)分别为15和14.5个月,临床获益率分别为75.0%和76.4%。胆碱能症状、黏膜炎均表现轻微。Ⅲ/Ⅳ度迟发性腹泻发生率分别为9.5%和23.5%,Ⅲ/Ⅳ度粒细胞减少发生率分别为14.3%和35.2%。结论两种方案治疗晚期大肠癌疗效无差别,每周方案毒性反应更低,均可作为晚期大肠癌的一线、二线化疗方案。更多还原

【Abstract】 Objective To evaluate the efficacy,the survival duration and the adverse effects of two different dose-densities of irinotecan(CPT-11) combined with LD-FP regimen in treatment of advanced colorectal cancer.Methods Group A including 21 patients was treated with CPT-11 60 mg/m2 iv on days 1,8 and 15.Group B including 17 patients was treated with CPT-11 150 mg/m2 iv on day 1.The two groups received intravenous infusion of CPT-11 in conjunction with 5-Fu 300 mg/(m2·d) continuous infusion for 14 days,cisplatin 5 mg/d iv for 5 days every week for 2 weeks and CF 100 mg/(m2·d)for 14 days respectively.All the regimens were repeated every 3 weeks.Results The ORR were 20.0% and 23.5%,respectively,mTTP of both groups was 5 months.MST were 15 and 14.5 months respectively.The clinical benefit rates were 75.0% and 76.4%,respectively.Acute cholinergic syndrome and mucositis in both groups were mild.The incidences of grade Ⅲ/Ⅳ delayed diarrhea were 9.5% and 23.5% and incidences of grade Ⅲ/Ⅳ neutropenia were 14.3% and 35.2%,respectively.Conclusions There was no difference in the therapeutic effect between the two regimens.The weekly regimen was less toxic.Both regimens can be the therapeutic choice for advanced colorectal cancer.更多还原